CRISPR Therapeutics AG (MEX:CRSP) EPS (Basic) : MXN-51.74 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG EPS (Basic)?

CRISPR Therapeutics AG's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was MXN-19.89. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-51.74.

CRISPR Therapeutics AG's EPS (Diluted) for the three months ended in Sep. 2024 was MXN-19.89. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-51.74.

CRISPR Therapeutics AG's EPS without NRI for the three months ended in Sep. 2024 was MXN-19.89. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -51.74.

During the past 3 years, the average EPS without NRI Growth Rate was 28.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, CRISPR Therapeutics AG's highest 3-Year average EPS without NRI Growth Rate was 28.40% per year. The lowest was -94.60% per year. And the median was -51.55% per year.

CRISPR Therapeutics AG EPS (Basic) Historical Data

The historical data trend for CRISPR Therapeutics AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG EPS (Basic) Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

23.20

-105.23

101.96

-162.99

-32.93

CRISPR Therapeutics AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-24.56	19.18	-23.73	-27.30	-19.89

CRISPR Therapeutics AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CRISPR Therapeutics AG's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2607.414	-	0)	/	79.221
	=	-32.91

CRISPR Therapeutics AG's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1692.224	-	0)	/	85.235
	=	-19.85

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-51.74

CRISPR Therapeutics AG (MEX:CRSP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CRISPR Therapeutics AG EPS (Basic) Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

CRSP:USA 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.